Ingalls & Snyder LLC lifted its holdings in shares of Nephros, Inc. (OTCMKTS:NEPH) by 104.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 134,539 shares of the company’s stock after purchasing an additional 68,750 shares during the quarter. Ingalls & Snyder LLC owned 1.69% of Nephros worth $1,339,000 at the end of the most recent quarter.
Separately, Millennium Management LLC acquired a new stake in Nephros in the 3rd quarter valued at approximately $313,000.
Shares of OTCMKTS NEPH opened at $9.75 on Thursday. The company has a current ratio of 2.56, a quick ratio of 1.86 and a debt-to-equity ratio of 0.26. Nephros, Inc. has a 12 month low of $3.69 and a 12 month high of $11.35. The stock has a 50 day moving average of $9.07 and a 200-day moving average of $7.57. The company has a market capitalization of $81.94 million, a P/E ratio of -18.06 and a beta of 0.85.
Nephros (OTCMKTS:NEPH) last issued its earnings results on Wednesday, November 6th. The company reported ($0.10) EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.10). Nephros had a negative return on equity of 56.37% and a negative net margin of 49.93%. The company had revenue of $3.10 million during the quarter, compared to the consensus estimate of $3.12 million. Analysts predict that Nephros, Inc. will post -0.63 EPS for the current fiscal year.
NEPH has been the topic of several recent analyst reports. Zacks Investment Research lowered Nephros from a “buy” rating to a “hold” rating in a research report on Friday, November 15th. Maxim Group reaffirmed a “buy” rating and set a $16.00 price target on shares of Nephros in a research report on Tuesday, January 7th. Finally, Benchmark initiated coverage on Nephros in a research report on Thursday, October 24th. They set a “buy” rating and a $16.00 price target on the stock.
Nephros Company Profile
Nephros, Inc, a commercial stage medical device and commercial product company, develops and sells liquid purification filters and hemodiafiltration (HDF) systems primarily in the United States. It operates through two segments, Water Filtration and Renal Products. The company's ultrafilters are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from water borne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities.
Featured Article: How to invest using market indexes
Receive News & Ratings for Nephros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nephros and related companies with MarketBeat.com's FREE daily email newsletter.